T he burden of chronic kidney disease, end-stage renal disease (ESRD) and kidney transplant (KTX) in the US non-Hispanic Black (NHB) population cannot be overstated. Based on the 2010 Census and 2014 USRDS data, NHBs represent 12.6% of the US population, yet 32.2% of those with ESRD, 33.9% of those on the KTX waiting list and 22.2% of those that received a KTX are NHB. Thus, NHBs are substantially overrepresented among the ESRD and KTX waiting list populations, but are significantly less likely to receive a KTX, as compared with non-Hispanic whites (NHWs).
1,2 After transplant, NHBs are at significantly higher risk of graft loss. The most recent US-based data from the United Network of Organ Sharing (UNOS) registry data demonstrate that NHB KTXs have a 5-year graft/patient survival rate of 61%, which compares with 74% in NHWs, a 13% absolute lower graft survival rate. Unfortunately, based on the definition used in public reporting of US data, it is not easy to gain an appreciation of the magnitude of this disparity for death-censored graft failure. 3 The current definition for graft loss used by the US registry and regulatory bodies overseeing transplantation, including UNOS, the Scientific Registry of Transplant Recipients, and the Centers for Medicare and Medicaid Services (CMS) encompass a composite of both graft loss (return to dialysis or retransplantation) and death, [4] [5] [6] this is otherwise referred to as overall graft loss. This definition has been in place since the U.S. Congress passed the National Organ Transplantation Act in 1984, which established the Organ Procurement and Transplantation Network and contracted with UNOS to be the steward of these data. The choice of a composite overall graft loss definition is logical from a regulatory oversight standpoint, because death is a clinically meaningful event, and a kidney allograft cannot be deemed as functional in a deceased recipient. Thus, using this composite definition to compare and benchmark transplant programs' performance metrics is appropriate. 6 Unfortunately, within the realm of racial disparities reporting, a composite definition of graft loss that includes death as an outcome is potentially troublesome on a number of levels. This is because the mortality rates across racial cohorts in the KTX population are not uniform, and depending on the time period and data source, NHBs actually accrue a survival advantage while on dialysis and potentially posttransplant, despite their disproportionately high incidence of allograft failure. 3, 7 Thus, this composite definition of graft loss likely masks the true magnitude of the disparity that NHB KTX recipients experience. Furthermore, concentrating on death as the event of interest may detract from intervening early on mutable factors impacting graft loss based on a signal of deteriorating allograft function that can be yielded by monitoring death-censored graft survival. This issue can be highlighted from a recently published study analyzing the impact of advanced age on NHB disparities for graft loss in KTX using the US registry data. The authors found that advanced age attenuated the rates of overall graft loss, because the relative hazard for overall graft loss decreased with advancing age. However, when death-censored graft loss was used as the primary outcome of interest, this attenuation in the disparity was not as dramatic, a finding that remained significant even in those 65 years or older. 8 As little has changed in the magnitude of racial disparities in KTX over the past 40 years, despite significant research efforts, this issue has real-life implications, because most large-scale studies use this national registry data to conduct detailed analyses of the prevailing etiologies surrounding racial disparities in KTX. [9] [10] [11] The aim of this analysis was to use a unique US-based data set that contains detailed baseline and longitudinal clinical data to establish and quantify the impact of the current overall graft loss definition on suppressing the true disparity magnitude in US NHB KTX outcomes.
MATERIALS AND METHODS

Study Design and Patients
This was an institutional review board and Veteran Affairs (VA) HSR&D approved longitudinal cohort study analyzing US national data of adult solitary KTX recipients. This cohort of KTX recipients was developed by obtaining data compiled from the Unites States Renal Data System (USRDS) and national VA patient medical and administrative databases obtained over a 10-year period, with transplants that were performed between January 2001 and December 2007 and followed up until December 2010 or death. Data from the National Patient Care Databases was used to construct a national sample of all veterans who are identified via International Classification of Disease, version 9 codes as having a renal transplant, are at least 18 years of age at the time of transplant, of any race, ethnicity, or sex, with baseline and follow-up data available to analyze. Exclusion criteria included, non-VA patients, those transplanted outside of the specified timeframe or recipients of multiorgan transplants. After the initial analysis demonstrated that there were only 367 patients (0.7%) that were not either NHW or NHB, the study was focused on these 2 racial cohorts.
Data Variables and Definitions
A summary of the data variables, definitions, and outcomes used in this study is displayed in Table S1 (SDC, http://links.lww.com/TP/B247). The National Patient Care Databases was the source for the VA data, which is essentially the complete electronic medical record for veterans receiving care within the VA system. The Decision Support System Clinical National Data Extracts Lab Results database contains laboratory data for VA patients, including hemoglobin A1Cs (A1Cs) and lipid levels. These VA data were linked to the USRDS data using scrambled social security numbers. Data variables for baseline transplant characteristics and graft outcomes were captured using the USRDS/CMS databases. The primary dependent outcomes of interest included time to graft loss, death (overall, either before or after graft loss), and death-censored graft loss. Independent variables used in multivariable models included transplant characteristics, sociodemographics, and the presence and control of diabetes, hypertension, and dyslipidemia.
Statistical Analysis
Univariate summary results are reported in means ± SD for continuous variables, with categorical data presented in percentages. Adjusted estimates from multivariable models are presented as hazard ratios (HR) with 95% confidence intervals (CI). Continuous variables were compared using t tests, whereas categorical variables were compared using the Pearson χ 2 test. Kaplan-Meier analyses were used to estimate univariate survival rates, with the Log rank test used for statistical comparison. For multivariate modeling, we used a 2-stage approach to jointly model the random and fixed effects longitudinal data with the baseline fixed variables for the outcomes of time to graft loss, death, and death-censored graft loss. This methodology is commonly used with longitudinal data and has been well validated with previous studies (see Supplemental Methodology, SDC, http://links.lww.com/TP/B247). In the first stage, a linear mixed model is used, where both covariate effects and subjectspecific random effects are modeled parametrically. In the second stage, a Cox model for time to event is used. The mixed model for the longitudinal process and the Cox model for the survival process are associated through common covariates in both models and the stochastic dependence between the random-effects terms and outcomes. 12, 13 For a full description of this modeling methodology, assumptions made, and justification of this approach, please see the Supplemental Methodology section (SDC, http://links.lww.com/TP/B247), which also includes assessment of missing data. Covariates that were included in the models are listed in Table 1 and include sociodemographics, comorbidities, immunologic characteristics, and donor characteristics. Concordance was excellent for linked variables. These were then entered into the model in a forward sequential blocked method, first starting with only race, then adding demographics, comorbidities, immunologic characteristics and finally, posttransplant characteristics. For the Cox model, appropriateness of the assumption of proportionality of hazards was determined by examining log{−log(time)} plots and by testing the coefficients of the interactions of time with the respective covariate in a multivariate analyses. Residual analysis was used to assess goodness of fit of the models from each stage and to check the assumption of normality in the longitudinal part. None of these assumptions were violated. Models were compared using standard goodness of fit analyses. Statistical significance was based on a P value less than 0.05. Statistical analyses were performed using SAS (version 9.4, SAS Institute Inc, Cary, NC).
RESULTS
Study Population and Characteristics
This study included 4918 US veterans that received solitary KTXs between 2001 and 2007, which includes 3306 NHW (67%) and 1612 NHB (33%) recipients. The mean follow-up time for the entire cohort was 6.0 ± 2.2 years, which was similar between NHB and NHW patients (6.0 ± 2.2 vs 6.1 ± 2.2, respectively; P = 0.1436). The study flow diagram, detailing how this cohort was developed, is displayed in Figure 1 . Table 1 presents the baseline and follow-up characteristics for the total study cohort and compares these between NHW and NHB patients. At the time of transplant, there were a number of significant differences, when comparing NHW with NHB recipients. The NHB cohort was younger, less likely to be married, more likely to reside in the south, more likely to be unemployed, and more likely to have hypertension as the primary disease causing ESRD. The NHB recipients were also less likely to receive a living donor, but more likely to receive a donor organ from a NHB or deceased after cardiac death. Finally, NHB recipients had more HLA mismatches, spent longer on dialysis and were less likely to have a preemptive transplant, as compared with NHW patients.
Posttransplant, there were also a number of notable differences between groups. The NHB patients were more likely to receive cytolytic induction therapy, develop delayed graft function, develop new-onset diabetes after transplant, and have graft loss. The NHB were less likely to die after transplant.
Clinical Outcomes
The NHB recipients had an estimated 5-year overall graft survival rate of 77%, which was significantly lower, as compared with NHW patients (81%, P = 0.006). The estimated 5-year patient survival rates were higher in NHB recipients, as compared with NHWs (90% vs. 87%, P = 0.001), whereas 5-year death-censored graft survival rates demonstrated the largest disparity (84% NHB vs 90% NHW; P < 0.001). 2. Forest plot displaying the unadjusted and fully adjusted hazard ratios in NHB, as compared with NHW, for the outcomes of graft loss, death, and death-censored graft loss. In the unadjusted analyses, NHB race is a significant risk factor for overall graft loss and death-censored graft loss, while NHB race is a protective factor for death. In the fully adjusted models, NHB race is only a significant risk factor for death-censored graft loss. Continued next page (NHB vs. NHW) and the three outcomes of interest (graft loss, death, and death-censored graft loss). The NHB recipients had 19% higher risk of graft loss, 17% lower risk of death, and 67% higher risk of death-censored graft loss, all of which were statistically significant (P = 0.002, 0.0118, and <0.0001, respectively). Table 2 displays the covariates and associated HRs, 95% CIs, and P values for the outcomes of graft loss, death, and death-censored graft loss for the fully adjusted model. After controlling for all covariates, NHB race was no longer a significant predictor for overall graft loss (HR, 1.08; 95% CI, 0.91-1.28) or death (HR, 0.84; 95% CI, 0.67-1.06); however, NHB recipients had 38% higher risk of deathcensored graft loss, after full adjustment (HR, 1.38; 95% CI, 1.12-1.71, P = 0.0044). These fully adjusted HRs and 95% CIs are also displayed in Figure 2 , to allow for direct comparison to the unadjusted values.
For overall graft loss, other covariates, outside of race, that were independent predictors included recipient age, residing in the midwest or northeast, primary disease of hypertension, history of PVD, previous KTX, donor age, receiving a living donor, donor race, HLA mismatches, current PRA, corticosteroid use and cardiovascular disease (CVD) risk factor control measures (A1C and low-density lipoproteins (LDL) intercepts and slopes). For death, independent predictors included recipient age, residing in the West, Midwest or Northeast, marital status, primary disease of hypertension, history of PVD, baseline diabetes, previous KTX, living donor, current PRA and CVD risk factor control measures (LDL intercept and slope). For death-censored graft loss, independent predictors included recipient race, recipient age, residing in the northeast, donor age, living donor, extended criteria donor, and all CVD risk factor control measures (A1C, LDL, and systolic blood pressure intercepts and slopes). Variables that were significant predictors across all 3 outcomes included recipient age, residing in the northeast, receiving a living donor, and CVD risk factor control measures.
The sequential modelling results for the 3 outcomes of interest are displayed in Table 3 , along with the models goodness of fit. For overall graft loss, the fully adjusted model demonstrated that NHB race was no longer a significant risk factor (HR, 1.08; 95% CI, 0.91-1.28). Sequential modelling demonstrated that the domain that provided the greatest degree of confounding was transplant characteristics and donor information, which decreased the HR from 1.35 to 1.09. The analysis of mortality demonstrated that in univariate analysis, NHB race was a significant protective factor (HR, 0.83; 95% CI, 0.72-0.96); after sequential modelling, the magnitude of this effect was unchanged, but statistical significance was lost (HR, 0.84; 95% CI, 0.67-1.06). Finally, for the outcome of death-censored graft failure, sequential modelling demonstrated that after full adjustment, NHB race continued to be a strong risk factor. As compared with NHWs, NHBs had a 38% higher risk of death-censored graft loss (HR, 1.38; 95% CI, 1.12-1.71). The models for mortality and death-censored graft loss both had substantially lower Akaike information criteria, indicating better goodness of fit, as compared with the model for overall graft loss.
DISCUSSION
The results of this analysis demonstrate that US NHB KTX recipients experience significant disparities in graft survival rates, when death is censored as an event. This disparity persists even after controlling for numerous covariates. When the composite definition of overall graft loss is used, the magnitude of this disparity is reduced by more than 20%, to the point where statistical significance is lost. These results have important implications for public policy and reporting of outcomes in transplantation, because the current definition of graft loss within the US regulatory oversight bodies, UNOS, Scientific Registry of Transplant Recipients, and CMS, all use the composite graft loss/death classification for public reporting and evaluation of program performance; thus, racial disparities are likely underappreciated through these reporting criteria. 3, 6, 7 This designation of overall graft loss has also become the standard used for US-based research analyses assessing this outcome, including a number of those analyzing racial disparities. 8, 10, [14] [15] [16] [17] Based on these results, we propose that US transplant regulatory agencies consider also reporting death-censored graft loss as a publicly reported outcome, with the hopes of helping researchers, clinicians, and the greater transplant community understand if racial equity in graft outcomes is truly being achieved. There are 2 important reasons why this should be done: (1) The current measure underestimates the magnitude of disparity, and (2) deterioration in graft function often precedes death-censored graft loss and could be used as a signal to trigger interventions impacting mutable risk factors for graft loss.
Previous pivotal studies assessing the magnitude and etiologies of disparities in NHB KTX recipients have used varying methodology to define graft loss. The original landmark study published in 1977 that first recognized racial disparities in KTX by Opelz et al 18 separated graft and patient survival and analyzed each outcome independently. These authors demonstrated a 10% absolute difference in graft survival at 3 years posttransplant (25% in blacks vs 35% in whites, P < 0.0001), whereas patient survival rates were similar. In 1983, researchers from the University of Alabama published a study demonstrating a 16% absolute difference in graft survival rates between black and white recipients (57% vs 73%; P = 0.002). 19 Yet, contrary to the Opelz et al 18 analysis, these authors defined graft loss as a composite of return to dialysis, nephrectomy, or death with a function graft. After this, in a comprehensive review article published by Kasiske et al 20 in 1991, which, similar to the Opelz article, analyzed graft and patient survival separately, demonstrated that NHB recipients had a significant disparity in graft outcomes, ranging from 7% to 20%, which was not demonstrated with patient survival in that race did not have an independent impact on recipient survival. In a more recent publication, Keith and Patrie 21 conducted a donor-paired racial analysis that compared specific causes of graft loss between NHB and whites. The results demonstrated that all causes of graft loss, particularly rejection and chronic allograft nephropathy, were significantly higher in NHB recipients. However, graft loss due to death (death with function) was similar between racial cohorts. Over the past 30 years, there are numerous additional examples within the transplant literature that demonstrate that racial disparities in graft outcomes are specifically related to loss of graft function, whereas mortality rates are similar between NHB and white KTX recipients. 10, 11, 22, 23 Thus, it is clear that to gain a better understanding of the true magnitude and etiology of this disparity, analyses should consistently focus on graft loss, without including death as an event (censure at the time of death). Given that there has been little change in the scope of this disparity, despite significant research efforts over the past 40 years, focusing on the true difference in outcomes may help elucidate the true etiologies of this public health issue. 7, 18 In this study, we report the results of the first systematic analysis of US national data to directly compare racial disparities as it specifically relates to 3 outcomes, overall graft loss, death, and death-censored graft loss. We did so using a unique database that linked USRDS and VA data to create a cohort that was rich in both baseline and follow-up clinical information. Furthermore, the data demonstrate that VA patients do not have race-based differences in access to care. Our results thus demonstrate the robust and true contribution of a flawed metric to the estimation of disparity. Our results clearly demonstrate differences in disparity based on how graft loss is defined. Using the composite definition demonstrates that controlling for baseline covariates mitigates outcomes disparity based on race; yet, using pure graft loss as a definition (censoring for death), it is clear that racial disparities persist, despite accounting for detailed donor and recipient variables. Thus, to gain a precise appreciation of the magnitude of racial disparities in transplant, these results support the use death-censored graft loss as a more accurate definition. As patients who have graft loss either go back on dialysis or are retransplanted, this definition has important patient and societal implications. 24, 25 The fact that racial disparities for death-censored graft loss persist despite controlling for numerous donor, recipient, and transplant characteristics is an interesting finding and may point to other potential etiologies. Although this analysis controlled for education and marital status, we did not account for other socioeconomic and ecologic factors, including income, substance abuse, family support, community support, or health literacy. Some of these clearly differ across race and have been associated with outcomes in transplantation. [26] [27] [28] Medication nonadherence was not accounted for, which may impact racial disparities as well. [29] [30] [31] Genetic factors, including gene variants in the donor (APOL1) and recipient (CYP P450 3A5), are more common in NHBs and have been associated with KTX outcomes. 32, 33 Finally, outside of patient-level factors, this study did not account for provider or systems-level issues (beyond geographical region) that may propagate racial disparities. Provider prescribing patterns and access to expert high-quality care are well known to differ across racial cohorts and influence outcomes in high-risk populations. [34] [35] [36] These patient, provider, and systems variables, which were not captured or controlled for in this analysis, may help to explain why NHB race continues to be a significant risk factor for death-censored graft loss, even after accounting for numerous sociodemographic factors.
There are a number of limitations to this analysis that are worthy of discussion. First, this analysis was confined to a veteran transplant population, and the number of female recipients was quite low at 2.4% of the study population. Thus, these results are not applicable to female transplant recipients. Using a veteran population also restricts the ability of this analysis to study the impact of insurance coverage and access to care on outcomes. As insurance coverage may greatly impact medication nonadherence, this is likely a major mediator for racial disparities in transplantation. However, previous studies have demonstrated that racial disparities are similar in magnitude between VA and non-VA populations, and using VA data allowed us to include numerous clinical variables that are missing or not available from previous studies that solely used the USRDS or CMS data sets. 37 Therefore, for the purposes of this analysis, which focused on racial disparities, the benefits provided by the use of VA data greatly outweigh the limitations of solely focusing on veteran patients. Another limitation of this analysis was its retrospective design and relatively short follow-up time, which may increase the risk for confounding and misclassification, potentially biasing the results. However, because we were able to link 2 databases with unique and overlapping data in a longitudinal format, we dramatically minimized these risks. We validated race, sex, and age by comparing them between the 2 data sets for accuracy, demonstrating high rates of congruence (100% for sex, 99.8% for age, and 97.0% for race). Using a national database with relatively large numbers of patients, as compared with previous studies, also strengthens these results. Thus, we feel this analysis provides a precise and unbiased estimate of the true magnitude of racial disparities within contemporary KTX. Finally, it is important to note that this analysis focused on US-based data sources and regulatory body definitions. Studies conducted outside the United States use varying definitions of graft loss, either including or excluding death as an event. [38] [39] [40] [41] [42] Thus, these results should only be applied to US-based transplant programs and US-based transplant regulatory agencies.
Our major finding is that death-censored graft survival is substantially different between NHB and NHW. Furthermore, this difference in death-censored graft survival was significantly associated with surrogates for the quality of clinical care including blood pressure, diabetes, and lipids control. The fact that this outcome is associated with process measures, such as CVD and blood pressure control, suggests that adequate control of these issues could impact graft loss. We have previously demonstrated that disparate CVD control is an important underpinning that could explain disparities of outcome among NHBs. [43] [44] [45] Thus, these often overlooked metrics could point toward ways to improve transplant outcomes among transplant recipients.
In summary, NHB KTX recipients experience significant outcomes disparities, which are primarily related graft function and not mortality. This large-scale national study, using detailed baseline and longitudinal clinical data, provides strong evidence to suggest that disparity researchers consider using death-censored graft loss the primary outcome of interest, in hopes of better elucidating causal factors for racial disparities in transplantation and determining whether equity is being achieved.
